Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis
CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE[1])–Anokion[2] SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced the initiation of patient dosing in its Phase 1 clinical trial to evaluate ANK-700 for the treatment of people with relapsing remitting multiple sclerosis (RRMS). The MoveS-it Study (Multiple Sclerosis Study of ANK-700 to Assess Safety and...